LymphedemaV1, PubMed, Checkpoint, bibRecord, 001B03

Impact of obesity on cancer survivorship and the potential relevance of race and ethnicity.

Identifieur interne : 001B03 ( PubMed/Checkpoint ); précédent : 001B02; suivant : 001B04

Impact of obesity on cancer survivorship and the potential relevance of race and ethnicity.

Auteurs : Kathryn H. Schmitz ; Marian L. Neuhouser ; Tanya Agurs-Collins ; Krista A. Zanetti ; Lisa Cadmus-Bertram ; Lorraine T. Dean ; Bettina F. Drake

Source :

Journal of the National Cancer Institute [ 1460-2105 ] ; 2013.

RBID : pubmed:23990667

Descripteurs français

KwdFr :
- Comorbidité, Facteurs de risque, Fatigue (étiologie), Groupes ethniques (), Humains, Indice de masse corporelle, Lymphoedème (étiologie), Neuropathies périphériques (étiologie), Obésité (), Obésité (ethnologie), Obésité (épidémiologie), Populations d'origine continentale (), Qualité de vie, Résultat thérapeutique, Survie sans rechute, Taux de survie, Tumeurs (), Tumeurs (ethnologie), Tumeurs (mortalité), Tumeurs (étiologie), Tumeurs du sein (), État de santé.
MESH :
- ethnologie : Obésité, Tumeurs.
- mortalité : Tumeurs.
- épidémiologie : Obésité.
- étiologie : Fatigue, Lymphoedème, Neuropathies périphériques, Tumeurs.
- Comorbidité, Facteurs de risque, Groupes ethniques, Humains, Indice de masse corporelle, Obésité, Populations d'origine continentale, Qualité de vie, Résultat thérapeutique, Survie sans rechute, Taux de survie, Tumeurs, Tumeurs du sein, État de santé.

English descriptors

KwdEn :
- Body Mass Index, Breast Neoplasms (complications), Breast Neoplasms (prevention & control), Comorbidity, Continental Population Groups (statistics & numerical data), Disease-Free Survival, Ethnic Groups (statistics & numerical data), Fatigue (etiology), Health Status, Humans, Lymphedema (etiology), Neoplasms (complications), Neoplasms (ethnology), Neoplasms (etiology), Neoplasms (mortality), Neoplasms (prevention & control), Neoplasms (therapy), Obesity (complications), Obesity (epidemiology), Obesity (ethnology), Peripheral Nervous System Diseases (etiology), Quality of Life, Risk Factors, Survival Rate, Treatment Outcome.
MESH :
- complications : Breast Neoplasms, Neoplasms, Obesity.
- epidemiology : Obesity.
- ethnology : Neoplasms, Obesity.
- etiology : Fatigue, Lymphedema, Neoplasms, Peripheral Nervous System Diseases.
- mortality : Neoplasms.
- prevention & control : Breast Neoplasms, Neoplasms.
- statistics & numerical data : Continental Population Groups, Ethnic Groups.
- therapy : Neoplasms.
- Body Mass Index, Comorbidity, Disease-Free Survival, Health Status, Humans, Quality of Life, Risk Factors, Survival Rate, Treatment Outcome.

Abstract

Evidence that obesity is associated with cancer incidence and mortality is compelling. By contrast, the role of obesity in cancer survival is less well understood. There is inconsistent support for the role of obesity in breast cancer survival, and evidence for other tumor sites is scant. The variability in findings may be due in part to comorbidities associated with obesity itself rather than with cancer, but it is also possible that obesity creates a physiological setting that meaningfully alters cancer treatment efficacy. In addition, the effects of obesity at diagnosis may be distinct from the effects of weight change after diagnosis. Obesity and related comorbid conditions may also increase risk for common adverse treatment effects, including breast cancer-related lymphedema, fatigue, poor health-related quality of life, and worse functional health. Racial and ethnic groups with worse cancer survival outcomes are also the groups for whom obesity and related comorbidities are more prevalent, but findings from the few studies that have addressed these complexities are inconsistent. We outline a broad theoretical framework for future research to clarify the specifics of the biological-social-environmental feedback loop for the combined and independent contributions of race, comorbid conditions, and obesity on cancer survival and adverse treatment effects. If upstream issues related to comorbidities, race, and ethnicity partly explain the purported link between obesity and cancer survival outcomes, these factors should be among those on which interventions are focused to reduce the burden of cancer.

DOI: 10.1093/jnci/djt223
PubMed: 23990667

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 001950
to stream PubMed, to step Curation: 001950

Links to Exploration step

pubmed:23990667

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Impact of obesity on cancer survivorship and the potential relevance of race and ethnicity.</title>
<author><name sortKey="Schmitz, Kathryn H" sort="Schmitz, Kathryn H" uniqKey="Schmitz K" first="Kathryn H" last="Schmitz">Kathryn H. Schmitz</name>
<affiliation><nlm:affiliation>Affiliations of authors: Center for Clinical Epidemiology and Biostatistics, Abramson Cancer Center Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA (KHS, LTD); Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA (MLN); Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD (TA-C, KAZ); Moores Cancer Center, University of California, San Diego, CA (LC-B); Department of Surgery, Washington University, St. Louis, MO (BFD).</nlm:affiliation>
<wicri:noCountry code="subField">MO (BFD)</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Neuhouser, Marian L" sort="Neuhouser, Marian L" uniqKey="Neuhouser M" first="Marian L" last="Neuhouser">Marian L. Neuhouser</name>
</author>
<author><name sortKey="Agurs Collins, Tanya" sort="Agurs Collins, Tanya" uniqKey="Agurs Collins T" first="Tanya" last="Agurs-Collins">Tanya Agurs-Collins</name>
</author>
<author><name sortKey="Zanetti, Krista A" sort="Zanetti, Krista A" uniqKey="Zanetti K" first="Krista A" last="Zanetti">Krista A. Zanetti</name>
</author>
<author><name sortKey="Cadmus Bertram, Lisa" sort="Cadmus Bertram, Lisa" uniqKey="Cadmus Bertram L" first="Lisa" last="Cadmus-Bertram">Lisa Cadmus-Bertram</name>
</author>
<author><name sortKey="Dean, Lorraine T" sort="Dean, Lorraine T" uniqKey="Dean L" first="Lorraine T" last="Dean">Lorraine T. Dean</name>
</author>
<author><name sortKey="Drake, Bettina F" sort="Drake, Bettina F" uniqKey="Drake B" first="Bettina F" last="Drake">Bettina F. Drake</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2013">2013</date>
<idno type="RBID">pubmed:23990667</idno>
<idno type="pmid">23990667</idno>
<idno type="doi">10.1093/jnci/djt223</idno>
<idno type="wicri:Area/PubMed/Corpus">001950</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001950</idno>
<idno type="wicri:Area/PubMed/Curation">001950</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001950</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001950</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001950</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Impact of obesity on cancer survivorship and the potential relevance of race and ethnicity.</title>
<author><name sortKey="Schmitz, Kathryn H" sort="Schmitz, Kathryn H" uniqKey="Schmitz K" first="Kathryn H" last="Schmitz">Kathryn H. Schmitz</name>
<affiliation><nlm:affiliation>Affiliations of authors: Center for Clinical Epidemiology and Biostatistics, Abramson Cancer Center Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA (KHS, LTD); Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA (MLN); Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD (TA-C, KAZ); Moores Cancer Center, University of California, San Diego, CA (LC-B); Department of Surgery, Washington University, St. Louis, MO (BFD).</nlm:affiliation>
<wicri:noCountry code="subField">MO (BFD)</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Neuhouser, Marian L" sort="Neuhouser, Marian L" uniqKey="Neuhouser M" first="Marian L" last="Neuhouser">Marian L. Neuhouser</name>
</author>
<author><name sortKey="Agurs Collins, Tanya" sort="Agurs Collins, Tanya" uniqKey="Agurs Collins T" first="Tanya" last="Agurs-Collins">Tanya Agurs-Collins</name>
</author>
<author><name sortKey="Zanetti, Krista A" sort="Zanetti, Krista A" uniqKey="Zanetti K" first="Krista A" last="Zanetti">Krista A. Zanetti</name>
</author>
<author><name sortKey="Cadmus Bertram, Lisa" sort="Cadmus Bertram, Lisa" uniqKey="Cadmus Bertram L" first="Lisa" last="Cadmus-Bertram">Lisa Cadmus-Bertram</name>
</author>
<author><name sortKey="Dean, Lorraine T" sort="Dean, Lorraine T" uniqKey="Dean L" first="Lorraine T" last="Dean">Lorraine T. Dean</name>
</author>
<author><name sortKey="Drake, Bettina F" sort="Drake, Bettina F" uniqKey="Drake B" first="Bettina F" last="Drake">Bettina F. Drake</name>
</author>
</analytic>
<series><title level="j">Journal of the National Cancer Institute</title>
<idno type="eISSN">1460-2105</idno>
<imprint><date when="2013" type="published">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Body Mass Index</term>
<term>Breast Neoplasms (complications)</term>
<term>Breast Neoplasms (prevention & control)</term>
<term>Comorbidity</term>
<term>Continental Population Groups (statistics & numerical data)</term>
<term>Disease-Free Survival</term>
<term>Ethnic Groups (statistics & numerical data)</term>
<term>Fatigue (etiology)</term>
<term>Health Status</term>
<term>Humans</term>
<term>Lymphedema (etiology)</term>
<term>Neoplasms (complications)</term>
<term>Neoplasms (ethnology)</term>
<term>Neoplasms (etiology)</term>
<term>Neoplasms (mortality)</term>
<term>Neoplasms (prevention & control)</term>
<term>Neoplasms (therapy)</term>
<term>Obesity (complications)</term>
<term>Obesity (epidemiology)</term>
<term>Obesity (ethnology)</term>
<term>Peripheral Nervous System Diseases (etiology)</term>
<term>Quality of Life</term>
<term>Risk Factors</term>
<term>Survival Rate</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Comorbidité</term>
<term>Facteurs de risque</term>
<term>Fatigue (étiologie)</term>
<term>Groupes ethniques ()</term>
<term>Humains</term>
<term>Indice de masse corporelle</term>
<term>Lymphoedème (étiologie)</term>
<term>Neuropathies périphériques (étiologie)</term>
<term>Obésité ()</term>
<term>Obésité (ethnologie)</term>
<term>Obésité (épidémiologie)</term>
<term>Populations d'origine continentale ()</term>
<term>Qualité de vie</term>
<term>Résultat thérapeutique</term>
<term>Survie sans rechute</term>
<term>Taux de survie</term>
<term>Tumeurs ()</term>
<term>Tumeurs (ethnologie)</term>
<term>Tumeurs (mortalité)</term>
<term>Tumeurs (étiologie)</term>
<term>Tumeurs du sein ()</term>
<term>État de santé</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Breast Neoplasms</term>
<term>Neoplasms</term>
<term>Obesity</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Obesity</term>
</keywords>
<keywords scheme="MESH" qualifier="ethnologie" xml:lang="fr"><term>Obésité</term>
<term>Tumeurs</term>
</keywords>
<keywords scheme="MESH" qualifier="ethnology" xml:lang="en"><term>Neoplasms</term>
<term>Obesity</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Fatigue</term>
<term>Lymphedema</term>
<term>Neoplasms</term>
<term>Peripheral Nervous System Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Tumeurs</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Breast Neoplasms</term>
<term>Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Continental Population Groups</term>
<term>Ethnic Groups</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Obésité</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Fatigue</term>
<term>Lymphoedème</term>
<term>Neuropathies périphériques</term>
<term>Tumeurs</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Body Mass Index</term>
<term>Comorbidity</term>
<term>Disease-Free Survival</term>
<term>Health Status</term>
<term>Humans</term>
<term>Quality of Life</term>
<term>Risk Factors</term>
<term>Survival Rate</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Comorbidité</term>
<term>Facteurs de risque</term>
<term>Groupes ethniques</term>
<term>Humains</term>
<term>Indice de masse corporelle</term>
<term>Obésité</term>
<term>Populations d'origine continentale</term>
<term>Qualité de vie</term>
<term>Résultat thérapeutique</term>
<term>Survie sans rechute</term>
<term>Taux de survie</term>
<term>Tumeurs</term>
<term>Tumeurs du sein</term>
<term>État de santé</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Evidence that obesity is associated with cancer incidence and mortality is compelling. By contrast, the role of obesity in cancer survival is less well understood. There is inconsistent support for the role of obesity in breast cancer survival, and evidence for other tumor sites is scant. The variability in findings may be due in part to comorbidities associated with obesity itself rather than with cancer, but it is also possible that obesity creates a physiological setting that meaningfully alters cancer treatment efficacy. In addition, the effects of obesity at diagnosis may be distinct from the effects of weight change after diagnosis. Obesity and related comorbid conditions may also increase risk for common adverse treatment effects, including breast cancer-related lymphedema, fatigue, poor health-related quality of life, and worse functional health. Racial and ethnic groups with worse cancer survival outcomes are also the groups for whom obesity and related comorbidities are more prevalent, but findings from the few studies that have addressed these complexities are inconsistent. We outline a broad theoretical framework for future research to clarify the specifics of the biological-social-environmental feedback loop for the combined and independent contributions of race, comorbid conditions, and obesity on cancer survival and adverse treatment effects. If upstream issues related to comorbidities, race, and ethnicity partly explain the purported link between obesity and cancer survival outcomes, these factors should be among those on which interventions are focused to reduce the burden of cancer.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23990667</PMID>
<DateCreated><Year>2013</Year>
<Month>09</Month>
<Day>18</Day>
</DateCreated>
<DateCompleted><Year>2013</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<DateRevised><Year>2017</Year>
<Month>02</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2105</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>105</Volume>
<Issue>18</Issue>
<PubDate><Year>2013</Year>
<Month>Sep</Month>
<Day>18</Day>
</PubDate>
</JournalIssue>
<Title>Journal of the National Cancer Institute</Title>
<ISOAbbreviation>J. Natl. Cancer Inst.</ISOAbbreviation>
</Journal>
<ArticleTitle>Impact of obesity on cancer survivorship and the potential relevance of race and ethnicity.</ArticleTitle>
<Pagination><MedlinePgn>1344-54</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1093/jnci/djt223</ELocationID>
<Abstract><AbstractText>Evidence that obesity is associated with cancer incidence and mortality is compelling. By contrast, the role of obesity in cancer survival is less well understood. There is inconsistent support for the role of obesity in breast cancer survival, and evidence for other tumor sites is scant. The variability in findings may be due in part to comorbidities associated with obesity itself rather than with cancer, but it is also possible that obesity creates a physiological setting that meaningfully alters cancer treatment efficacy. In addition, the effects of obesity at diagnosis may be distinct from the effects of weight change after diagnosis. Obesity and related comorbid conditions may also increase risk for common adverse treatment effects, including breast cancer-related lymphedema, fatigue, poor health-related quality of life, and worse functional health. Racial and ethnic groups with worse cancer survival outcomes are also the groups for whom obesity and related comorbidities are more prevalent, but findings from the few studies that have addressed these complexities are inconsistent. We outline a broad theoretical framework for future research to clarify the specifics of the biological-social-environmental feedback loop for the combined and independent contributions of race, comorbid conditions, and obesity on cancer survival and adverse treatment effects. If upstream issues related to comorbidities, race, and ethnicity partly explain the purported link between obesity and cancer survival outcomes, these factors should be among those on which interventions are focused to reduce the burden of cancer.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schmitz</LastName>
<ForeName>Kathryn H</ForeName>
<Initials>KH</Initials>
<AffiliationInfo><Affiliation>Affiliations of authors: Center for Clinical Epidemiology and Biostatistics, Abramson Cancer Center Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA (KHS, LTD); Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA (MLN); Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD (TA-C, KAZ); Moores Cancer Center, University of California, San Diego, CA (LC-B); Department of Surgery, Washington University, St. Louis, MO (BFD).</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Neuhouser</LastName>
<ForeName>Marian L</ForeName>
<Initials>ML</Initials>
</Author>
<Author ValidYN="Y"><LastName>Agurs-Collins</LastName>
<ForeName>Tanya</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y"><LastName>Zanetti</LastName>
<ForeName>Krista A</ForeName>
<Initials>KA</Initials>
</Author>
<Author ValidYN="Y"><LastName>Cadmus-Bertram</LastName>
<ForeName>Lisa</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y"><LastName>Dean</LastName>
<ForeName>Lorraine T</ForeName>
<Initials>LT</Initials>
</Author>
<Author ValidYN="Y"><LastName>Drake</LastName>
<ForeName>Bettina F</ForeName>
<Initials>BF</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>1U54CA155435</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>U01CA116850</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>U54 CA155496</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>U54-CA155850</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2013</Year>
<Month>08</Month>
<Day>29</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>J Natl Cancer Inst</MedlineTA>
<NlmUniqueID>7503089</NlmUniqueID>
<ISSNLinking>0027-8874</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Cancer. 2012 Apr 15;118(8 Suppl):2250-60</RefSource>
<PMID Version="1">22488699</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer. 2007 Jun 15;109(12):2410-9</RefSource>
<PMID Version="1">17510973</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2011 Jan 1;29(1):25-31</RefSource>
<PMID Version="1">21115856</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2007 Jun 20;25(18):2522-7</RefSource>
<PMID Version="1">17577029</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Gynecol Oncol. 2005 May;97(2):422-30</RefSource>
<PMID Version="1">15863140</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>BMJ. 2005 Jun 11;330(7504):1360</RefSource>
<PMID Version="1">15863436</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Obes Relat Metab Disord. 2001 May;25(5):662-8</RefSource>
<PMID Version="1">11360148</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Natl Cancer Inst. 2009 May 6;101(9):630-43</RefSource>
<PMID Version="1">19401543</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Med Sci. 2012;9(2):163-73</RefSource>
<PMID Version="1">22275855</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Gastroenterol. 2006 Oct;101(10):2308-18</RefSource>
<PMID Version="1">17032196</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2003 Apr 24;348(17):1625-38</RefSource>
<PMID Version="1">12711737</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Am Coll Surg. 1997 Dec;185(6):593-603</RefSource>
<PMID Version="1">9404886</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Prev Res (Phila). 2012 Jul;5(7):901-10</RefSource>
<PMID Version="1">22609763</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Natl Cancer Inst Monogr. 2004;(32):40-50</RefSource>
<PMID Version="1">15263040</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Cancer Surviv. 2010 Dec;4(4):405-14</RefSource>
<PMID Version="1">20862614</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2007 Jun 15;13(12):3611-6</RefSource>
<PMID Version="1">17575225</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Qual Life Res. 2007 Aug;16(6):947-60</RefSource>
<PMID Version="1">17457697</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Prev Res (Phila). 2011 Apr;4(4):544-51</RefSource>
<PMID Version="1">21325564</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer. 2007 Jan 15;109(2 Suppl):435-45</RefSource>
<PMID Version="1">17149759</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Breast Cancer Res Treat. 2010 Jan;119(1):145-53</RefSource>
<PMID Version="1">19731015</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Semin Hematol. 2000 Oct;37(4 Suppl 6):14-7</RefSource>
<PMID Version="1">11068951</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Gynecol Cancer. 2012 May;22(4):686-91</RefSource>
<PMID Version="1">22398707</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Cancer Surviv. 2009 Dec;3(4):212-22</RefSource>
<PMID Version="1">19760151</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Causes Control. 2008 Dec;19(10):1319-28</RefSource>
<PMID Version="1">18752034</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Gynecol Cancer. 2011 Dec;21(9):1525-32</RefSource>
<PMID Version="1">22080892</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Support Care Cancer. 2011 Jun;19(6):853-7</RefSource>
<PMID Version="1">21240649</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Breast J. 2010 Jan-Feb;16(1):48-54</RefSource>
<PMID Version="1">19889169</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer. 1996 Aug 1;78(3):471-9</RefSource>
<PMID Version="1">8697393</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2010 Mar 15;16(6):1884-93</RefSource>
<PMID Version="1">20215553</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer. 2011 Mar 1;117(5):948-56</RefSource>
<PMID Version="1">20945318</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Acta Oncol. 2000;39(3):389-92</RefSource>
<PMID Version="1">10987236</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Annu Rev Nutr. 2012 Aug 21;32:311-42</RefSource>
<PMID Version="1">22540252</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Public Health. 1983 Feb;73(2):171-8</RefSource>
<PMID Version="1">6600376</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Epidemiol Biomarkers Prev. 2010 Sep;19(9):2229-37</RefSource>
<PMID Version="1">20826830</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arch Surg. 2010 Nov;145(11):1055-63</RefSource>
<PMID Version="1">21079093</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Breast Cancer Res Treat. 2011 Sep;129(2):565-74</RefSource>
<PMID Version="1">21499688</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Breast Cancer Res Treat. 2006 Jun;97(3):245-54</RefSource>
<PMID Version="1">16331345</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Public Health. 2002 Jan;92(1):64-70</RefSource>
<PMID Version="1">11772763</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Support Care Cancer. 2011 Oct;19(10):1581-91</RefSource>
<PMID Version="1">20835835</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Breast Cancer Res Treat. 2010 Oct;123(3):627-35</RefSource>
<PMID Version="1">20571870</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer. 2012 May 15;118(10):2651-8</RefSource>
<PMID Version="1">22006057</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Med Sci Sports Exerc. 2010 Apr;42(4):665-71</RefSource>
<PMID Version="1">19952838</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Urol. 2005 Apr;173(4):1132-8</RefSource>
<PMID Version="1">15758721</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer. 2000 Dec 1;89(11):2176-86</RefSource>
<PMID Version="1">11147587</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Pain Symptom Manage. 2008 Nov;36(5):488-96</RefSource>
<PMID Version="1">18504096</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Obstet Gynecol Int. 2011;2011:308609</RefSource>
<PMID Version="1">22135678</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Cancer Surviv. 2009 Jun;3(2):89-98</RefSource>
<PMID Version="1">19437121</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer. 2012 May 1;118(9):2338-66</RefSource>
<PMID Version="1">22460733</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Am Coll Surg. 2009 Jun;208(6):1093-8</RefSource>
<PMID Version="1">19476897</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nurs Res. 2008 Nov-Dec;57(6):416-25</RefSource>
<PMID Version="1">19018216</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Surg. 2000 Apr;179(4):275-81</RefSource>
<PMID Version="1">10875985</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2011 Sep 1;29(25):3358-65</RefSource>
<PMID Version="1">21788570</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer. 2012 Apr 15;118(8 Suppl):2277-87</RefSource>
<PMID Version="1">22488702</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2007 Jan 20;25(3):277-84</RefSource>
<PMID Version="1">17159190</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer. 2007 Oct 15;110(8):1868-74</RefSource>
<PMID Version="1">17823909</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Epidemiol Biomarkers Prev. 2012 Aug;21(8):1260-71</RefSource>
<PMID Version="1">22695738</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer. 2011 Aug 15;117(16):3658-69</RefSource>
<PMID Version="1">21387260</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Acta Oncol. 2012 Jul;51(6):722-9</RefSource>
<PMID Version="1">22793038</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arch Intern Med. 2005 Jun 13;165(11):1267-73</RefSource>
<PMID Version="1">15956006</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Prev Res (Phila). 2010 Dec;3(12):1608-20</RefSource>
<PMID Version="1">20719902</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Orthop Clin North Am. 2011 Jan;42(1):123-7, vii</RefSource>
<PMID Version="1">21095441</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 2008 Nov 15;68(22):9512-8</RefSource>
<PMID Version="1">19010927</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer. 2007 Jun 15;109(12):2607-14</RefSource>
<PMID Version="1">17474128</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>BMC Public Health. 2009;9:88</RefSource>
<PMID Version="1">19320986</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Hematol Oncol. 2005 Jun;23(2):73-81</RefSource>
<PMID Version="1">16170828</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Oncol Nurs Forum. 2008 Sep;35(5):815-21</RefSource>
<PMID Version="1">18765328</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Gynecol Oncol. 2010 Oct;119(1):60-4</RefSource>
<PMID Version="1">20638109</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1403-9</RefSource>
<PMID Version="1">19366908</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer. 2009 Sep 1;115(17):4001-9</RefSource>
<PMID Version="1">19637244</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Breast Cancer. 2012 Aug;12(4):270-5</RefSource>
<PMID Version="1">22683281</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Anesth Analg. 2002 Dec;95(6):1788-92, table of contents</RefSource>
<PMID Version="1">12456460</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2003 Dec 15;21(24):4524-31</RefSource>
<PMID Version="1">14673039</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Natl Cancer Inst. 2006 Apr 19;98(8):521-9</RefSource>
<PMID Version="1">16622121</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Prev Res (Phila). 2011 Apr;4(4):486-501</RefSource>
<PMID Version="1">21233290</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):2913-23</RefSource>
<PMID Version="1">18990731</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Intern Med. 2006 Apr 18;144(8):541-53</RefSource>
<PMID Version="1">16618951</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2012 May 1;30(13):1553-61</RefSource>
<PMID Version="1">22473167</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Oncol Nurs Forum. 2004 May;31(3):633-9</RefSource>
<PMID Version="1">15146229</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Kidney Dis. 2009 Oct;54(4):638-46</RefSource>
<PMID Version="1">19515474</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur J Cancer. 2010 Nov;46(16):2879-88</RefSource>
<PMID Version="1">20605090</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2009 May 1;27(13):2157-62</RefSource>
<PMID Version="1">19307504</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Breast Cancer Res Treat. 2011 Dec;130(3):981-91</RefSource>
<PMID Version="1">21761159</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Breast Cancer Res Treat. 2009 Jan;113(2):383-91</RefSource>
<PMID Version="1">18297429</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Qual Life Res. 2007 Apr;16(3):413-28</RefSource>
<PMID Version="1">17279444</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Cancer Surviv. 2011 Jun;5(2):191-207</RefSource>
<PMID Version="1">21274649</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Br J Nurs. 2008 May 8-21;17(9):576-86</RefSource>
<PMID Version="1">18562992</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2011 Jul 1;29(19):2653-9</RefSource>
<PMID Version="1">21555684</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Rev Cancer. 2011 Dec;11(12):886-95</RefSource>
<PMID Version="1">22113164</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Clin Oncol. 2011 Jun;16(3):238-43</RefSource>
<PMID Version="1">21213009</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Psychooncology. 2006 May;15(5):382-97</RefSource>
<PMID Version="1">16155965</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Breast Cancer Res Treat. 2003 Sep;81(1):21-31</RefSource>
<PMID Version="1">14531494</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Cancer. 2011 Sep 1;129(5):1199-206</RefSource>
<PMID Version="1">21064096</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Cancer. 2011 Nov 15;129(10):2492-501</RefSource>
<PMID Version="1">21207419</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur J Haematol. 2011 Jan;86(1):23-31</RefSource>
<PMID Version="1">20874823</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Obstet Gynecol. 2009 Mar;200(3):288.e1-8</RefSource>
<PMID Version="1">19110220</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2012 Sep 1;30(25):3051-7</RefSource>
<PMID Version="1">22851566</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Breast Cancer Res Treat. 2011 Nov;130(2):635-44</RefSource>
<PMID Version="1">21717106</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer. 2008 Dec 1;113(11):3222-30</RefSource>
<PMID Version="1">18973178</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>QJM. 2005 May;98(5):343-8</RefSource>
<PMID Version="1">15820971</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer. 2011 May 1;117(9):1788-99</RefSource>
<PMID Version="1">21509756</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Cancer Surviv. 2012 Dec;6(4):398-406</RefSource>
<PMID Version="1">23054848</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2008 Mar 20;358(12):1250-61</RefSource>
<PMID Version="1">18354103</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>BMC Cancer. 2010;10:648</RefSource>
<PMID Version="1">21108799</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Cancer. 2007 May 1;120(9):1986-92</RefSource>
<PMID Version="1">17230509</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Psychooncology. 2007 Dec;16(12):1059-68</RefSource>
<PMID Version="1">17549801</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Breast Cancer Res Treat. 2007 May;102(3):347-56</RefSource>
<PMID Version="1">17028980</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2009 Jul;10(7):653-62</RefSource>
<PMID Version="1">19556163</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Breast Cancer Res Treat. 2007 Nov;106(1):85-95</RefSource>
<PMID Version="1">17260096</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer. 2007 Feb 15;109(4):675-84</RefSource>
<PMID Version="1">17211863</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>JAMA. 2012 Feb 1;307(5):491-7</RefSource>
<PMID Version="1">22253363</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Breast Cancer Res Treat. 2012 Apr;132(2):729-39</RefSource>
<PMID Version="1">22187127</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Natl Cancer Inst. 2003 Oct 15;95(20):1545-8</RefSource>
<PMID Version="1">14559877</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 2002 May 15;62(10):2942-50</RefSource>
<PMID Version="1">12019176</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Epidemiol. 2006 Mar;16(3):197-205</RefSource>
<PMID Version="1">16137893</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Psychooncology. 2004 Jun;13(6):408-28</RefSource>
<PMID Version="1">15188447</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Fam Pract. 1996 Sep;43(3):265-70</RefSource>
<PMID Version="1">8797754</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Breast Cancer Res Treat. 2007 Nov;106(1):135-41</RefSource>
<PMID Version="1">17295046</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer. 2012 Apr 15;118(8 Suppl):2261-9</RefSource>
<PMID Version="1">22488700</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Med Sci. 2001 Apr;321(4):249-79</RefSource>
<PMID Version="1">11307867</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Obesity (Silver Spring). 2009 Apr;17(4):796-802</RefSource>
<PMID Version="1">19148123</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>BMC Cancer. 2009;9:42</RefSource>
<PMID Version="1">19183472</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Urol. 2010 Feb;183(2):629-33</RefSource>
<PMID Version="1">20018324</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Breast Cancer. 2005 Aug;6(3):260-6; discussion 267-9</RefSource>
<PMID Version="1">16137438</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer. 2012 Aug 15;118(16):4024-31</RefSource>
<PMID Version="1">22252966</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer. 2010 Dec 15;116(24):5740-8</RefSource>
<PMID Version="1">20734399</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Cancer. 2010 Feb 1;126(3):692-702</RefSource>
<PMID Version="1">19645011</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1401-10</RefSource>
<PMID Version="1">18559555</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Prev Res (Phila). 2012 Apr;5(4):583-92</RefSource>
<PMID Version="1">22318751</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2005 Aug 20;23(24):5501-10</RefSource>
<PMID Version="1">16110010</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Nurs. 2000 Apr;23(2):117-21</RefSource>
<PMID Version="1">10763282</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Am Coll Cardiol. 2009 Jun 16;53(24):2231-47</RefSource>
<PMID Version="1">19520246</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D015992" MajorTopicYN="N">Body Mass Index</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D044469" MajorTopicYN="N">Continental Population Groups</DescriptorName>
<QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005006" MajorTopicYN="N">Ethnic Groups</DescriptorName>
<QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006304" MajorTopicYN="N">Health Status</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000208" MajorTopicYN="Y">ethnology</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009765" MajorTopicYN="N">Obesity</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000208" MajorTopicYN="Y">ethnology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010523" MajorTopicYN="N">Peripheral Nervous System Diseases</DescriptorName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC3776266</OtherID>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year>
<Month>8</Month>
<Day>31</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2013</Year>
<Month>8</Month>
<Day>31</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2013</Year>
<Month>11</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">23990667</ArticleId>
<ArticleId IdType="pii">djt223</ArticleId>
<ArticleId IdType="doi">10.1093/jnci/djt223</ArticleId>
<ArticleId IdType="pmc">PMC3776266</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list></list>
<tree><noCountry><name sortKey="Agurs Collins, Tanya" sort="Agurs Collins, Tanya" uniqKey="Agurs Collins T" first="Tanya" last="Agurs-Collins">Tanya Agurs-Collins</name>
<name sortKey="Cadmus Bertram, Lisa" sort="Cadmus Bertram, Lisa" uniqKey="Cadmus Bertram L" first="Lisa" last="Cadmus-Bertram">Lisa Cadmus-Bertram</name>
<name sortKey="Dean, Lorraine T" sort="Dean, Lorraine T" uniqKey="Dean L" first="Lorraine T" last="Dean">Lorraine T. Dean</name>
<name sortKey="Drake, Bettina F" sort="Drake, Bettina F" uniqKey="Drake B" first="Bettina F" last="Drake">Bettina F. Drake</name>
<name sortKey="Neuhouser, Marian L" sort="Neuhouser, Marian L" uniqKey="Neuhouser M" first="Marian L" last="Neuhouser">Marian L. Neuhouser</name>
<name sortKey="Schmitz, Kathryn H" sort="Schmitz, Kathryn H" uniqKey="Schmitz K" first="Kathryn H" last="Schmitz">Kathryn H. Schmitz</name>
<name sortKey="Zanetti, Krista A" sort="Zanetti, Krista A" uniqKey="Zanetti K" first="Krista A" last="Zanetti">Krista A. Zanetti</name>
</noCountry>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B03 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001B03 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:23990667
   |texte=   Impact of obesity on cancer survivorship and the potential relevance of race and ethnicity.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:23990667" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a LymphedemaV1

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024

	Serveur d'exploration sur le lymphœdème
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le lymphœdème

Impact of obesity on cancer survivorship and the potential relevance of race and ethnicity.

Impact of obesity on cancer survivorship and the potential relevance of race and ethnicity.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki